Want to see SGHT full AI Analyst Report?
Top Page
Sight Sciences
(NASDAQ:SGHT)
Select Model
Select Model
Rating:58Neutral
Price Target:
$9.50
▲(14.18% Upside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by weak financial quality (large ongoing losses and continued free-cash-flow burn). Offsetting this, technicals show strong upward momentum and the earnings call signaled improving execution with raised revenue guidance and better expense discipline, though overbought indicators and litigation/reimbursement uncertainties temper the outlook.
Positive Factors
Raised revenue outlook and accelerating growth
Raised 2026 revenue guidance to $88–$92M, alongside Q2 growth of 20%, indicates improving commercial execution across glaucoma and dry eye. If sustained, higher procedure adoption and recurring disposables can expand the revenue base and support operating leverage over coming quarters.
Negative Factors
Persistent losses and negative cash generation
The company remains materially unprofitable and cash-flow negative despite improving loss metrics. Continued operating burn can require additional funding, constrain investment flexibility, and delay the point at which growth translates into internally generated capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Raised revenue outlook and accelerating growth
Raised 2026 revenue guidance to $88–$92M, alongside Q2 growth of 20%, indicates improving commercial execution across glaucoma and dry eye. If sustained, higher procedure adoption and recurring disposables can expand the revenue base and support operating leverage over coming quarters.
Read all positive factors
Sight Sciences (SGHT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$495.24M
Dividend YieldN/A
Average Volume (3M)307.94K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue Growth9.27%
EPS Growth41.98%
CountryUS
Employees186
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.56
Shares Outstanding55,087,990
10 Day Avg. Volume275,196
30 Day Avg. Volume307,939
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)6.47
Price to Sales (P/S)5.35
P/FCF Ratio-13.82
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue3.09
Enterprise Value/Gross Profit3.51
Enterprise Value/Ebitda-10.01
Forecast
1Y Price Target
$10.17Price Target Upside22.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$90.32M
Sight Sciences Business Overview & Revenue Model
Company Description
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical Sys...
How the Company Makes Money
Sight Sciences generates revenue primarily from selling its eye-care medical devices and the associated consumables used in procedures. A key revenue stream comes from glaucoma products, where the OMNI Surgical System is placed/used by ophthalmic ...
Sight Sciences Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call presented multiple strong operational and commercial positives — 20% total revenue growth, record Interventional Dry Eye traction, continued Interventional Glaucoma momentum, raised full-year guidance, improved operating metrics, and payer/product milestones (Aetna coverage expansion and OMNI Ultra clearance). Key risks discussed include one-time tariff refund contributions to margin, ongoing Alcon litigation and related cash/liability implications (~$55M judgment and royalties), remaining uncertainty around broader Dry Eye reimbursement timing, seasonality and tougher comps in the back half, and planned incremental investments that will increase OpEx. Overall, the company demonstrated clear progress toward growth and cash-flow improvement while acknowledging contingent risks that investors should monitor.Positive Updates
Strong Overall Revenue Growth
Total revenue of $23.4M in Q2 2026, up 20% year-over-year — the company's highest quarterly growth rate since 2023 and second consecutive quarter of double-digit growth.
Negative Updates
One-Time Tariff Refunds Inflated Margins
Q2 gross margin benefited from $1.4M in tariff refunds; Interventional Glaucoma margin included a $1.2M benefit (ex-refunds IG margin = 86%, in line with prior year), signaling part of the margin improvement was non-recurring.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Overall Revenue Growth
Total revenue of $23.4M in Q2 2026, up 20% year-over-year — the company's highest quarterly growth rate since 2023 and second consecutive quarter of double-digit growth.
Read all positive updates
Company Guidance
Management raised full‑year 2026 revenue guidance to $88–$92M (up 14%–19% vs. 2025, vs. prior $83–$89M), with Interventional Glaucoma narrowed to $79–$81M (up 4%–7%, vs. prior $77–$81M) and Interventional Dry Eye raised to $9–$11M (vs. prior $6–$8M and vs. $1.6M in 2025); they lowered full‑year adjusted operating expense guidance to $92–$94M (up 5%–7% vs. 2025, down from $93–$96M prior guidance). For Q3 they expect total revenue growth in the mid‑to‑high teens, IG growth in the mid‑single digits and IDE ≈ $3M; management reiterated plans to invest selectively while maintaining discipline and said current cash/opex positioning supports a path to cash‑flow breakeven without raising equity (Q2 cash $79.8M; debt $40M).Sight Sciences Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
56
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 83.38M | 77.36M | 79.87M | 81.06M | 71.33M | 48.96M |
| Gross Profit | 73.34M | 66.67M | 68.28M | 69.17M | 58.97M | 40.35M |
| EBITDA | -25.75M | -32.79M | -45.90M | -49.41M | -81.02M | -57.77M |
| Net Income | -29.76M | -38.43M | -51.51M | -55.55M | -86.24M | -62.96M |
Balance Sheet | ||||||
| Total Assets | 104.87M | 115.30M | 142.84M | 166.65M | 213.07M | 280.19M |
| Cash, Cash Equivalents and Short-Term Investments | 79.75M | 91.97M | 120.36M | 138.13M | 185.00M | 260.69M |
| Total Debt | 41.97M | 40.77M | 40.36M | 35.41M | 34.98M | 34.21M |
| Total Liabilities | 51.98M | 51.36M | 55.32M | 46.44M | 53.00M | 48.08M |
| Stockholders Equity | 52.89M | 63.94M | 87.52M | 120.22M | 160.08M | 232.11M |
Cash Flow | ||||||
| Free Cash Flow | -23.33M | -29.92M | -22.74M | -47.98M | -76.94M | -53.35M |
| Operating Cash Flow | -23.24M | -29.69M | -22.35M | -47.18M | -75.97M | -52.54M |
| Investing Cash Flow | -93.00K | -224.00K | -385.00K | -791.00K | -970.00K | -813.00K |
| Financing Cash Flow | 1.85M | 1.79M | 4.96M | 1.10M | 1.25M | 252.53M |
Sight Sciences Technical Analysis
Positive
8.32
Price Trends
8.49
Positive
6.99
Positive
5.93
Positive
Market Momentum
0.11
Negative
56.61
Neutral
79.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGHT, the sentiment is Positive. The current price of 8.32 is below the 20-day moving average (MA) of 8.76, below the 50-day MA of 8.49, and above the 200-day MA of 5.93, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 56.61 is Neutral, neither overbought nor oversold. The STOCH value of 79.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SGHT.
Sight Sciences Risk Analysis
Sight Sciences disclosed 52 risk factors in its most recent earnings report. Sight Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sight Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $74.58M | 4.78 | 9999.00% | ― | 3.26% | ― | |
59 Neutral | $479.68M | -10.70 | 231.87% | ― | 1.00% | 26.76% | |
58 Neutral | $495.24M | -16.10 | -50.64% | ― | 9.27% | 41.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $221.05M | -2.76 | 273.71% | ― | 25.25% | -9.85% | |
45 Neutral | $37.83M | -0.72 | -152.35% | ― | 11.96% | 6.12% |
* Healthcare Sector Average
SGHT
Sight Sciences
8.99
3.82
73.89%
RCEL
Avita Medical
15.51
11.72
309.23%
LNSR
LENSAR
6.07
-5.79
-48.82%
TLSI
TriSalus Life Sciences
3.59
-1.43
-28.49%
CVRX
CVRx
1.42
-8.93
-86.28%
Sight Sciences Corporate Events
Business Operations and StrategyExecutive/Board Changes
Sight Sciences Appoints New Chief Legal Officer Rashid
Positive
Aug 10, 2026
On August 6, 2026, Sight Sciences’ board appointed veteran healthcare lawyer Kashif Rashid as Chief Legal Officer and Corporate Secretary, effective August 10, 2026, succeeding Jeremy Hayden, who will depart his role on the same date and rem...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Sight Sciences lifts guidance after strong Q2 results
Positive
Aug 5, 2026
Sight Sciences, Inc. is a U.S.-based eyecare technology company focused on interventional solutions for glaucoma and dry eye disease, including implant-free glaucoma procedures like OMNI and SION and the TearCare system for dry eye. Operating in t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.